InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: eightisenough post# 289128

Saturday, 08/01/2020 5:53:06 PM

Saturday, August 01, 2020 5:53:06 PM

Post# of 426269
e-

Robert Bradway, as CEO, from Amgen ... Please don't say cannot get him (offering 15 M will do it

Are you sure?

2019: $19,6 million
2018: $18,6 million
2017: $16,8 million

they JUST VOTED on NEW compensation, correct?

Nope. Read the proxy carefully.

give me a break. espcially when he knew the sec. cons. WAS AN ISSUE at uspto-

???

The USPTO examiner considers the (first) 3 Graham factor only ... makes a conclusion ... sends it to the applicant. The applicant submit the SCs and the examiner reevaluate the conclusion.

In case of Amarin the examiner determined prima facie obviousness (based on the 3 Graham factor) but granted the patent(s) after considered the SCs.

SCs were anything but were not an issue at the USPTO ...

Eu must be sold/partnership immediately

Why? Why is it so urgent?

EU approval will not come earlier as end of November (shortest, best case scenario) but more likely it will be approved in Q1 2021 (normal timeline, after Phase III of the process ... not a slow walk).

Best,
G

Disclosure: I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News